The involvement of Quality by Design within the realm of pharmaceuticals

Author 1st Saurabh Srivastava
srivastavasaurabh996@gmail.com
School of Pharmaceutical Sciences, Chhatrapati Shahu ji Maharaj University, Kanpur India.

Author 2nd Dr. Ajay Kumar
Ajaykumarmpharm08@gmail.com
School of Pharmaceutical Sciences, Chhatrapati Shahu ji Maharaj University, Kanpur.

Author 3nd Vinayak Dasharath Gaikwad
Gaikwadvinu10@gmail.com
Central University of South Bihar, Gaya, India

Author 4rt Sudhanshu Sagar
sudhanshu8126426224@gmail.com
Moradabad Educational Trust Group Of Institution Faculty Of Pharmacy, Moradabad

Author 5th Rohit Kumar
Rk1029826@gmail.com
Department of Pharmaceutical Sciences Babasaheb Bhimrao Ambedkar University Lucknow, India

(Corrosponding Author) Shweta Singh Verma
shweta@csjmu.ac.in
School of Pharmaceutical Sciences, Chhatrapati Shahu ji Maharaj University, Kanpur India.

Abstract

In defense of The Impression of Quality by Design, it is demonstrated that excellence is a habit rather than only an act. In a very short period of time, the pharmaceutical sector has recently shown a great deal of interest in Quality by Design (QbD). It serves as a liaison between the pharmaceutical sector and the FDA, the drug regulatory agency, whose approach to the development of pharmaceutical products is primarily scientific, risk-based, comprehensive, and proactive. In an effort to guarantee the predetermined quality goods, QbD has aided in the development of novel formulations, new drug delivery systems, and new production techniques. One of QbD's main features is that it offers a tool for targeted and effective medication creation.

It can be used with analytical techniques. The Quality Target Product Profile (QTPP), Critical Quality Attributes (CAQ), Design space, Control strategy, and lifecycle management are important components of the Quality by Design approach. Quality by design is being used to a number of new studies using the HPLC approach. We also provide a quit assessment of medication delivery based on the patient's BMR in Quality by Design in Biopharmaceuticals.

Keywords: - Quality Target Product Profile (QTPP), Risk management, Application of QbD, Drug discovery

Introduction

Drug innovation and ongoing improvement have been made easier by quality by design over the course of the product lifecycle. As per the International Council for Harmonization of Technical Standards for Human Use of Pharmaceuticals, Quality By Design is essentially described as follows in the ICH guidelines: "A methodical approach to development that is founded on sound science and quality risk managements, with a focus on product and process understanding and control, starting with predetermined goals." Additionally, it demonstrates how industry and drug regulatory bodies may collaborate to advance the development of pharmaceutical products using a proactive, risk-based, scientific, and holistic approach. [1-3]. It focuses mostly on designing and developing medication formulations. The United States Food and Drug Administration (USFDA) took the initial move toward incorporating the quality paradigm into pharmaceutical development and regulatory practice in response to the low quality of pharmaceutical products. Regarding this, a 2004 concept paper that emphasized the idea of agency for transforming the quality paradigm took the following form:Pharmaceutical cGMP in the twenty-first century. Safety needs to take precedence than merely fixing quality issues.The results in the other metrics can be empowered by quality as the driving factor. Therefore, it is necessary to plan properly and include quality into both the product and the service in order to prevent future failures. Joseph Moses Juran, a well-known expert on quality, summed up the idea of quality by design by saying that quality may be planned and that the majority of issues related to quality stem from the initial planning of quality. In every industry, the concepts of QbD have been applied to improve the quality of processes and products. The pharmaceutical industry is spending billions of dollars on drug discovery and development in an effort to create highquality products that are consistently manufactured to provide the desired performance, owing to the significance of powerful drugs

with safe profiles[4-5]. Compared to final product testing alone, quality by design (QbD) offers insights early in the development process. In order to maintain the required level of product quality, quality by design established how the pharmaceutical formulation design and development are linked to the development process as well as manufacturing procedures. To guarantee that the information on the subject is established and used in an independent and integrated manner, guidelines and mathematical models are employed. [6-7] . Thus, the purpose of this review paper is to address implementation-related issues while offering a thorough knowledge of QbD from a variety of perspectives. The main characteristics of quality of design are: it is a tool for targeted and effective medication development; it is also based on the idea that quality is a continuum; it can be used to analytical methodologies; and it can be utilized at any stage of the drug's life cycle. Additionally, QbD offers several positive attributes, such as eliminating batch failures and minimizing deviations and expensive investigations. It avoids issues with regulatory compliance and boasts an effective, adaptable, and agile system. In addition, it examines the many components of quality by design, much as Pharmaceutical Development does. These together with the facilitators provide the essential framework for the Quality-by-Deadlines (QbD) approach to development. Determining the Crucial Process Parameters and Critical Quality Attributes, Determining the Design Space, Determining the Quality Target Product Profile (QTPP), and Determining the Quality Attributes are some examples of these steps. Despite its emphasis on quality, the pharmaceutical business has not been able to match other sectors in terms of productivity and production efficiency [8-9]. The pharmaceutical business demonstrates the cost of revalidation, the use of product specifications as the main control mechanism, better development decisions, etc. in the current context.The term "eventual breifing of the aspects of a pharmacological product's quality that, in theory, should be met to guarantee the intended quality while accounting for the product's efficacy and protections." (quality target product profile, or QTPP) is proposed. The quality target product profile was extensively utilized in the plan's development, along with clinical and commercial decisionmaking, contacts with regulatory agencies, and risk management. The TPP technique is used to produce the fundamental base composition of the optimal dosage form. Aspects like clinical performance and manufacturability are taken into consideration when developing the product and procedure. Additionally significant. Fulfilling these TPP standards is a prerequisite for QbD. "The physical, chemical, biological, or microbiological feature or attribute that has to

be managed, either directly or indirectly, to guarantee that the product satisfies the required standards for performance, stability, safety, and efficiency is known as CQA," according to the International Committee on Harmonization's definition of CQA. According to this definition, CQA does not include the intended levels of safety, efficiency, stability, or performance Design space is described as "the multidimensional combination and interaction of process scales that have been established to provide assurance of quality with input variables (e.g., material attributes)"," is another important component of QbD. FDA guidelines state that while a product is in production and can be produced without a formal design space, defining the design space is accessible. Nevertheless, this method can help to better understand and achieve overall management of a system [10-13]



Fig 1. Process control

Definition

In accordance with the most recent [ICH Q8(R1)] guidelines "The Organized Approach to Development," which starts with predetermined goals and places a strong emphasis on understanding products and processes as well as process control, is founded on operation control and process assessment, which are in turn based on solid science and quality risk management.

And in line with ASTM (American Society for Testing and Materials) E-2500: "Quality by Design principles ought to be implemented to guarantee that crucial elements are incorporated into the system throughout the specification and design phase." [6] "Quality of Design" (QbD) is an addition that involves creating tests and controls throughout the development phase based on the systematic maximum of understanding and utilizing the information acquired throughout the product's life-cycle to work on an atmosphere of continuous improvement. It also includes a more thorough comprehension of crucial process and product attributes.

QBD in Pharmaceutical Development [8-10]

Recent years have seen significant advancements in production information, quality management systems, and risk management in the pharmaceutical business, which strives to keep up with the fast progressing technologies. With the use of these new instruments, pharmaceutical companies may identify, investigate, address, and avoid issues while continually enhancing the medication production process. To ensure that information on the subject is found and used in an autonomous and integrated fashion, guidelines and mathematical models are employed. Despite its emphasis on quality, the pharmaceutical industry has not been able to match other sectors and businesses in terms of productivity and production efficiency. In the pharmaceutical industry today, the main methods of control are product standards, offline analysis for in-process needs, and the cost of corroboration.

Methodical Approach to Development

It starts with predetermined goals and places a strong emphasis on understanding goods and processes as well as process control.Products together with profile requirements in line with the intended in vivo functionality of the product. As a science-based advanced method, Qbd offers a foundation for improving and correcting industrial operations without requiring further regulatory filings or inspection. Furthermore, process understanding produced by QbD can facilitate technology transfer and increase its efficiency.

Opportunities [7-8]

This system is more effective, flexible, and agile. It also boosts manufacturing efficiency, lowers costs, eliminates waste and project rejections, and builds a scientific knowledge base for all products. It also improves industry-science interactions, guarantees consistency in information, and integrates risk management.

Seven steps of quality by design start up plan

1. The industry employs a freelance specialist in quality by design.

2. The specialist examines your findings. Structure and procedure, with the specialist leading a gap analysis

3. Using your whole own design studio, it maintains a fundamental quality.

4. After that, going over the expert's findings and advice.

5. Manufacturing and formulation procedures are planned. The resources are allocated based on the important quality aspects of the final product, which need to be regulated to match the desired profile.

6. Keep the impartial specialist on staff as your "Project Assurance" consultant. Product caliber

7. The procedure is regularly reviewed and revised to ensure consistent quality.

Designing in Products

Products are made to fulfill the demands of patients and performance standards. Processes are created to reliably satisfy the quality characteristics of the goods. It is known that setting raw material and process parameters has an impact on the quality of the final output. Process variability's critical sources are located and managed. To ensure constant quality throughout time, the processes are continuously reviewed and improved.

Components of Quality by Design [11-13]

Quality Target Product Profile (QTPP)

QTPP is defined by the FDA (Food and Development Authority) as the quality qualities associated with the product's safety and effectiveness. Pharmacokinetic considerations, dosage

forms, distribution methods, dose strengths, container closing systems, routes of administration, and drug product quality standards (such as sterility, purity, stability, and drug release) may all be included. The QTPP includes details about the dosage form, application method, packaging, appearance, and diagnosis in addition to defining the quantitative objectives for the drug's properties (such as solubility, potency, impurity, and stability). The quantitative objectives, release profiles, and other performance requirements unique to each product are included in the QTPP. The QTPP incorporates bioequivalence for generic products. Since the QTPP contains tests for characteristics like stability and bioequivalence that aren't done in the batch, it isn't a specification. Only the patient-related product performance is included in the QTPP. For example, the QTPP should contain the dissolution but not the particle size if the particle size is important for the dissolving of solid oral product. a learning, iterative, life-cycle approach that maximizes therapy results and decision-making for the benefit of the patient. It is crucial to recognize that only patient-relevant product performance elements should be included in QTPP. Tablet hardness or density, for instance, could be specified for process monitoring, however maybe outside of QTPP. Furthermore, if a solid oral product's ability to dissolve depends on particle size, then dissolving should be included in the QTPP but not particle size. [13-14]

Critical Quality Attributes [12-14]

It is necessary to identify the critical quality attributes, which include those that determine potency, purity, and surrogate for bioavailability, among others. It is based on how superior attributes influence the overall quality, safety, and effectiveness of the product. To ensure the necessary level of product quality, it is defined as "A physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution." They are frequently associated with pharmaceutical products, source materials (drug ingredient, additive), and intermediates (in process materials). These indicate that CQAs are subgroups of QTPP that might be altered by changes made to formulation or process variables. For instance, QTPP could contain extra quality features of the medication product, including strength and dose form, which are not included in CQA since they won't change during the medication development process. However, they will also be included in CQA as formulation or process parameters have the potential to alter QTTP features such as assay, content uniformity, dissolution, and permeation flux. For example, the CQAs of drug material and drug

product.The ICH guidelines for risk assessment are used in the acceptance of CQAs (Q9). Prioritization goods knowledge which encompasses the total laboratory, nonclinical and clinical experience with a certain product-quality aspect is essential for carrying out these risk assessments. This corpus of knowledge may also contain relevant data from related chemicals and data from book references. Together, these findings provide support for the relationship between the CQA and product efficacy and safety.

Quality Risk Management (QRM)

According to the FDA, risk management is a strategic safety program created to reduce product risk via the use of one or more instruments or treatments. It is a methodical procedure for identifying, managing, sharing, and reviewing risks to the drug product's quality over the course of its lifespan.[17] The ICH Q9 recommendation: A risk management process may be started and followed with the help of quality risk management. QRM is a crucial component of QbD since it aids in determining the degree to which key material attributes (CMA) and critical process parameters (CPP) have an influence on CQAs. This information can then be used to help prioritize the CQAs. [13-14] . They have a specific role in intricate procedures, notably those involving biologics.



Fig 2. Quality Risk Management (QRM)

Failure mode effects analysis (FMEA)

One of the risk-assessment instruments that is most frequently employed in the pharmaceutical sector is the FMEA. It is a methodical and proactive way to find and lessen the possibility of a process breakdown. Any mistakes or flaws in a procedure, substance, design, or piece of machinery are represented as failure modes. FMEA is a method to assess the impact of failures and prioritize them based on the identification of failure types [15] . Then, risk control procedures may be followed to steer clear of these failure scenarios. A deep comprehension of the process is necessary since FMEAs need a solid grasp of causes and consequences. [16] .

QRM of typical manufacturing process by FMEA approach

The initial steps in this case study's risk identification were based on previous knowledge about the drug's ingredient, excipient, and manufacturing method. The management team and the

project's QRM specialists received the risk analysis results through document. Through presentations at different industry forums, the company's other development sites' personnel were also informed about the knowledge acquired from this risk assessment.

Fault tree analysis (FTA)

The tools presuppose that a process or product will malfunction. A failure mode tree serves as a visual representation of the findings. This may be used to look into complaints or deviations to thoroughly understand their underlying causes and make sure that the planned improvements will fix the problems and not create new ones.

Hazard analysis and critical control points (HACCP)

It offers thorough documentation to demonstrate product or process expertise by defining control and monitoring criteria. A process or product's concern for both quality and safety is included in the definition of danger. Hazard analysis, identifying the critical control point, setting the critical limit, putting in place a mechanism to monitor the critical control point, and setting up a record-keeping system are all part of it. Additionally, this might be applied to recognize and control the risk posed by chemical, biological, and physical dangers.

Design Space

The FDA acknowledges the limitations of current drug development methods and endorses the QbD idea in conjunction with ICH. Accordingly, the pharmaceutical sector places a great deal of importance on the design space. Design spaces are intricate combinations of input factors (such as material qualities), how those variables interact with one another, and process parameters that have been shown to guarantee quality [5-6][19-20]. It is possible to set up a design space for both multiple unit operations and single unit processes. Although defining a design space is not necessary because knowledge of the product and process may be built without one, One can apply for one-factor-at-time (OFAT) techniques, which modify only one factor or variable at a time while leaving others constant, in accordance with FDA guidelines. However, when researching two or more components and using the Design of Experiment (DOE) approach to quality, those who modify many input variables at the same time are more effective. [21, 22]. The benefits of developing a design space are clear, and it serves as a means of demonstrating the

evolution of process understanding. One of the difficulties in effectively utilizing design space is the expense associated with its creation. Comprehensive data from the fewest possible trials, which examines impacts separately by changing all operational factors at once, allows for the provision of insight regarding the interactions between different variables.

Control Strategies

According to definitions, a control strategy is "all planned sets of controls derived from current understanding of the product and process that assures process performance and product quality." " in ICH Q 10. No matter how sophisticated or how basic, a control strategy must be implemented, whether it is created with an advanced or minimum method (QbD). Tests of the completed product are used as a control method in the most sophisticated items. Control strategies are typically replaced with inline controls in products produced with the QbD technique. Control strategies make sure that the process stays inside the parameters that the design space specifies. To guarantee that the standards for product quality are fulfilled, a risk-based approach to control plan development is necessary. The QTPP is the first step in developing the control plan. The primary objective of the initial research is to describe the active component and the significant physical, chemical, biological, and microbiological characteristics of the mixture. The majority of the time, it is difficult to manage the attributes of input materials (drug ingredient, additive, principal packaging materials, etc.) based on knowledge of how such qualities affect the processability or quality of the final product[26]. Although the notion of control strategy is not new, it is strongly tied to both criticality and design in the new approach that is emerging within QbD. The control method in the QbD approach necessitated a deeper comprehension of the product and process. Additionally, QbD offers more information than the basic method, expanding the alternatives for control strategies in areas that call for more time and specialty. The primary objective of the initial research is to describe the active component and the significant physical, chemical, biological, and microbiological characteristics of the mixture. The process development is also specified at this point.



Fig 3. Example of Control Strategy for QbD process

Implementing Control Measures in Industrial Manufacturing

The comprehension of a process including the robustness of control strategy kept growing during the product's manufacture. Opportunities for upgrading, changing, or continuously enhancing the control strategy should be presented by the implementation of product and process reviews inside the pharmaceutical quality system during the commercial production process. A pharmaceutical quality system should be modified if needed to facilitate the adoption of the QbD technique in the control strategy. Pharmacies should have pharmaceutical quality systems that offer the requisite technical and administrative audits when changes need to be made to product information, papers, operation processes, and systems in order to get the relevant permissions and evaluations [28].

Advantages of following a Quality by design -based Control Strategy

The expenses and rates of analytical methods, control systems, and quality risk assessments should be matched with the income needed for manufacturing-related investments. Sustainability is promoted by the adoption of environmentally friendly practices; it includes PAT applications in QbD. Non-initiative approaches often reduce operator exposure to chemicals and/or

potentially harmful items. The expenses associated with the removal and recycling of waste dissolvers are decreased, and the analysis times are shortened, as a result of the reduction in the number of tests required to release the batch through the use of online and inline approaches. Applying a control strategy that makes use of the advanced method guarantees process improvement over time and lowers the likelihood of faulty batches.

QbD has increased the efficiency in manufacturing as

Incorporating the clinic and manufacturing into the design process Reducing the amount of unpredictability in a project, fixing technical issues, and designing better goods that pose fewer manufacturing challenges Reducing waste and total manufacturing costs, improving goods and manufacturing processes continuously, reducing the quantity and complexity of analytical texts, and implementing real-time releases are all ways to increase productivity by preventing losses.

Licensing flexibility [19-21]

By incorporating the QbD idea into an already-existing product, licensing flexibility may be implemented. Improved process comprehension reduces the number of audits and shortens the authority's approval time. Reducing the manufacturing support needed for post-licensing modifications, using new technologies without getting license permission, encountering fewer difficulties during the audit and receiving approval more quickly, and coming to a scientific consensus between the government and industry.

The ICH Q8, Q9, Q10 GUIDELINES: THE FOUNDATION OF QbD[18-23]

The cornerstones of QbD are the ICH Guidelines of Q8 for Pharmaceutical Development, Q9 for Quality Risk Management and Q10 for Quality Systems. Although the ICH-Q8 guidelines do not apply to data during the clinical trial stage of a product, it is still important to take these guidelines' tenets into consideration. The ICH-Q8 rules can also be applied to a variety of different items, although doing so requires obtaining the necessary regulatory authority. Extension enables additional resolution of important ideas presented in the central guideline. In addition to ICH-Q8 (R1) claims that the purpose of the addendum is to clarify the concepts and resources related to the applicant's usage of quality by design (QbD) in the design space, as stated in the main Q8 document, rather than to create new standards.



Fig 4. The Foundation of QbD

Benefits of Implementing QbD for FDA [25-28]

It improves the scientific basis for reviews, allows for greater coordination across reviews, boosts the quality of the material in regulatory submissions, increases decision-making flexibility, and incorporates a variety of disciplines.Makes sure that judgments are based on science rather than, say, empirical data.

Advantages for the industry

Based on process and risk understanding, it guarantees better product design with fewer manufacturing issues and fewer manufacturing supplements needed for post-market modifications. It also opens the door to potential savings in manufacturing costs overall, reduces waste, and ensures less hassle during reviews, fewer deficiencies, and quicker approvals.

Conclusion

The ultimate objective of a well-characterized method development activity is to create a dependable process that, when used within predetermined parameters, can be shown to consistently deliver data that satisfies predetermined criteria with high degrees of certainty. Analytical method development and assessment can benefit from the application of QbD. To ascertain the linkages, all plausible components (the inputs) and all crucial analytical answers (the outputs) are examined throughout method development. An technique that is similar to that outlined in ICH Q8 and Q9 for process development identifies critical analytical variables. QbD is becoming a more significant and popular approach in the development of pharmaceutical products. Although QbD works best when applied at the product/process design level, production and quality assurance settings should also use it. When the QbD concept is included into product development, manufacturers may enhance manufacturing and drastically lower batch failure rates, giving patients access to high-quality medications. Additionally, drug regulatory agencies will have more faith in the goods' solid quality. QbD focuses on every element that is needed in a high-quality product, including determining the quality profile of medicinal products, ranking input factors for optimization, improving and validating QbD technique, and, finally, validating, scaling up, producing, and using QbD software. A risk assessment must to be carried out each time a procedure is modified. A method evaluation and, if necessary, an equivalency exercise should be carried out when modifications are found to have the potential to move the methods outside of their known design space in order to make sure the method performance requirements are still maintained.

References

1. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 7(6), 2004, 10–15.

2. Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006.

3. Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.

4. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by design: Concepts for ANDAs, The AAPS Journal, 10, 2008, 268–276.

5. FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance).

6. (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.

7. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. Analytical Chemistry, 59, 1987, 624A–637A.

8. Yu LX, Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceutical Research, 25, 2008, 781–791.

9. Munson J, Gujral B, Stanfield CF, A review of process analytical technology (PAT) in the U.S. pharmaceutical industry. Current Pharmaceutical Analysis, 2, 2006, 405–414.

10. Leuenberger H, Puchkov M, Krausbauer E, Betz G, pharmaceutical granules, Is the granulation end-point a myth, Powder Technology, 189, 2009, 141–148.

11. Miller CE, Chemometrics and NIR: A match made in heaven, Am. Pharm. Rev. Food and Drug Administration CDER, Guidance for industry, Q8 pharmaceutical development; 2:41–48, 2006 .

12. Nasr M. Risk-based CMC review paradigm, Advisory committee for pharmaceutical science meeting, 2004.

13. Food and Drug Administration CDER. Guidance for industry: Immediate release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1995.

14. Food and Drug Administration CDER. Guidance for industry: Modified release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.

15. Food and Drug Administration CDER. Guidance for industry: Non sterile semisolid dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.

16. Food and Drug Administration CDER. Guidance for industry: Changes to an approved NDA or ANDA, 2004.

17. Frank T, Brooks S, Murray K, Reich S, Sanchez E, Hasselbalch B, et al. Defining Process Design Space: A Risk-Management Case Study (Part 1). Pharmaceutical Technology. 2011;35(7):77.

18. Keizer JA, Vos J-P, Halman JIM. Risks in new product development: devising a reference tool. R&D Management. 2005;35(3):297-309.

19. Altan S, Bergum J, Pfahler L, Senderak E, Sethuraman S, Vukovinsky KE. Statistical Considerations in Design Space Development Part I of III. Pharmaceutical Technology. 2010;34(7):66-70.

20. Harms J, Wang X, Kim T, Yang X, Rathore AS. Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation. Biotechnology Progress. 2008;24(3):655-62.

21. Huang J, Kaul G, Cai C, Chatlapalli R, Hernandez-Abad P, Ghosh K, et al. Quality by design case study: An integrated multivariate approach to drug product and process development. Int. J. Pharm. 2009;382(1-2):23-32.

22. Altan S, Bergum J, Pfahler L, Senderak E, Sethuraman S, Vukovinsky KE. Statistical Considerations in Design Space Development Part II of III. Pharmaceutical Technology. 2010;34(8):52-60.

23. Shivhare M, McCreath G. Practical Considerations for DoE Implementation in Quality By Design. BioProcess International. 2010;8(6):22-30.

24. Korakianiti E, Rekkas D. Statistical thinking and knowledge management for quality- driven design and manufacturing in pharmaceuticals. Pharm Res. 2011;28(7):1465-79.

25. US Food and Drug Administration. Guidance for industry Q8, Q9, & Q10 Questions and Answers. US Department of Health and Human Service (FDA, Rockville, MD, 2012).

26. Trivedi B. Quality by desing (QbD) in pharmaceuticals.Int J Pharm Pharm Sci. 2012;4(1):17-29.

27. US Food and Drug Administration. Guidance for industry: Q11 development and manufacture of drug substances. US Department of Health and Human Service (FDA, Rockville, MD, 2012).

28. Raw AS, Lionberger R, Yu LX. Pharmaceutical equivalence by design for generic drugs: modified-release products. Pharm Res. 2011;28(7):1445-1453.